Early fusion rates after direct lateral lumbar interbody fusion with bone-morphogenetic protein

H Zhang, B Dial, C Brown - International Journal of Spine Surgery, 2021 - ijssurgery.com
Background: Direct lateral (transpsoas) lumbar interbody fusion (LLIF) reportedly achieves
union by 1 year postoperatively, but how soon fusion occurs after these minimally invasive …

Fusion rates of lateral lumbar interbody fusion using recombinant human bone morphogenetic protein-2

AA Nourian, J Harrington, PA Pulido… - Global Spine …, 2019 - journals.sagepub.com
Study Design: Retrospective observational case series. Objectives: Lateral lumbar interbody
fusion (LLIF) has been widely performed with recombinant human bone morphogenetic …

Lateral lumbar interbody fusion–clinical outcomes, fusion rates and complications with recombinant human bone morphogenetic protein-2

MB Morton, YY Wang, AJ Buckland… - British Journal of …, 2023 - Taylor & Francis
Background The authors report an Australian experience of lateral lumbar interbody fusion
(LLIF) with respect to clinical outcomes, fusion rates, and complications, with recombinant …

Complication rates following stand-alone lateral interbody fusion: a single institution series after 10 years of experience

P Godolias, ZL Tataryn, S Frieler, R Nunna… - European Journal of …, 2023 - Springer
Purpose This retrospective single institution study's goal was to analyze and report the
complications from stand-alone lateral lumbar interbody fusions (LLIF). Methods This …

Fusion rate for stand-alone lateral lumbar interbody fusion: a systematic review

MK Manzur, ME Steinhaus, SS Virk, B Jivanelli… - The Spine Journal, 2020 - Elsevier
BACKGROUND Lateral lumbar interbody fusion (LLIF) is used to treat multiple conditions,
including spondylolisthesis, degenerative disc disorders, adjacent segment disease, and …

Retrospective analysis of L5–S1 axial lumbar interbody fusion (AxiaLIF): a comparison with and without the use of recombinant human bone morphogenetic protein-2

PC Gerszten, WD Tobler, RJ Nasca - The Spine Journal, 2011 - Elsevier
BACKGROUND CONTEXT: Since approval by the Food and Drug Administration in 2002,
use of recombinant human bone morphogenetic protein-2 (rhBMP-2) to promote spinal …

Perioperative risk factors for early revisions in stand-alone lateral lumbar interbody fusion

C Rentenberger, I Okano, SN Salzmann, F Winter… - World Neurosurgery, 2020 - Elsevier
Background Lateral lumbar interbody fusion can be performed without supplemental
posterior instrumentation. Previous reports have shown favorable results with stand-alone …

Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions

CL Adams, K Ogden, IK Robertson, S Broadhurst… - Spine, 2014 - journals.lww.com
Study Design. Retrospective cohort study. Objective. To compare clinical outcomes, fusion
rates, and rates of complications in posterior lumbar interbody fusions (PLIFs) and …

Which Approach Leads to More Reoperations in Single-Level, Open, Posterior Lumbar Fusion: Transforaminal Lumbar Interbody Fusion or Posterolateral Fusion …

AR Tang, H Chanbour, AM Steinle… - International Journal of …, 2023 - ijssurgery.com
Background Transforaminal lumbar interbody fusion (TLIF) and posterolateral fusion (PLF)
without an interbody device are two common approaches for single-level, open posterior …

Rates of Postoperative Complications and Approach-related Neurological Symptoms After L4–L5 Lateral Transpsoas Lumbar Interbody Fusion Compared With Upper …

MT Nolte, SD Gandhi, AQ Nguyen, ZK Siyaji… - Clinical Spine …, 2023 - journals.lww.com
Study Design: This was a retrospective comparative study. Objective: To compare the
likelihood of approach-related complications for patients undergoing single-level lateral …